跳至主要内容
临床试验/NCT00280605
NCT00280605已完成4 期

Study of the Outcome of Patients With Lower Urinary Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Alfuzosin 10 mg Once Daily for 3 Months in China

Sanofi0 个研究点目标入组 200 人开始时间: 2005年8月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Sanofi
入组人数
200
主要终点
Spontaneous adverse events

研究概览

简要总结

The aim of the study is to collect, under daily practice conditions, clinical data on the safety profile and the efficacy of a new formulation of alfuzosin administered once daily in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
Male
接受健康志愿者

入选标准

  • Ambulatory patients suffering from Lower Urinary Tract Symptoms suggestive of Benign Prostatic Hyperplasia

排除标准

  • Patients requiring Benign Prostatic Hyperplasia surgery immediately or within the 12 following months
  • Patients previously not improved by an alpha 1-blocker treatment
  • Patients whose urinary symptoms are satisfactorily controlled on other Benign Prostatic Hyperplasia medication (alpha 1-blockers and 5-ARI)
  • Known hypersensitivity to alfuzosin
  • History of postural hypotension or syncope
  • Combination with other alpha 1-blockers
  • Hepatic insufficiency
  • Unstable angina pectoris
  • Severe concomitant condition threatening life

结局指标

主要结局

Spontaneous adverse events

Blood pressure and heart rate measured in sitting position

International Prostate Symptom Score (IPSS) and quality of life index

DAN-PSS sexual function score

PSA levels measured at baseline

Maximum flow rate and residual urine

次要结局

未报告次要终点

研究者

发起方
Sanofi
申办方类型
Industry

相似试验

ALF-ONE : ALFuzosin ONcE Daily | 临床试验